Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Withdrawal Clear all
Completed Phase 4 Interventional Results available

Prevention of Recurrence in Depression With Drugs and CT

NCT00057577
View directory record Official record
Conditions
Depression
Interventions
Cognitive Therapy, Medications
Behavioral · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
3
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 5, 2026, 9:29 AM EDT
Active, not recruiting Phase 1 Interventional

BHV-7000 Responsive Neurostimulation System (RNS) Study

NCT07125261
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
BHV-700
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 5, 2026, 9:29 AM EDT
Completed Not applicable Interventional Results available

Scoliosis-Specific Exercises for At-Risk AIS Curves

NCT02807545
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Scoliosis Specific Exercises
Behavioral
Lead sponsor
Texas Scottish Rite Hospital for Children
Other
Eligibility
10 Years to 17 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 5, 2026, 9:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Menopausal Sleep Fragmentation and Body Fat Gain

NCT03047330
View directory record Official record
Conditions
Menopause
Interventions
Estradiol withdrawal, Fragmented sleep
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 5, 2026, 9:29 AM EDT
Completed Not applicable Interventional

Use of SVS Device to Improve Outcomes for Neonatal Opioid Withdrawal Syndrome.

NCT04834297
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
Prapela SVS mattress
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
0 Days to 2 Days
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 5, 2026, 9:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation

NCT01685996
View directory record Official record
Conditions
Nicotine Dependence
Interventions
zonisamide, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 5, 2026, 9:29 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effects of Multiple Concussions in Retired NHL Players

NCT02746523
View directory record Official record
Conditions
Cognitive Deficits, Proprioceptive Disorders
Interventions
Sensory Organization Test, Biomarkers, Conners' Adult ADHD Rating Scale (CAARS), Depression Scale, Cognitive Assessment
Other · Genetic
Lead sponsor
New York Institute of Technology
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Sep 5, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

NCT02724020
View directory record Official record
Conditions
Clear-cell Metastatic Renal Cell Carcinoma
Interventions
Everolimus, MLN0128, MLN1117
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Los Angeles, California • Venice, Florida • West Palm Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 5, 2026, 9:29 AM EDT
Completed Not applicable Interventional Results available

Patient Acceptance and Preference Among Screening Modalities for Detection of Barrett's Esophagus

NCT04301986
View directory record Official record
Conditions
Barrett Esophagus, GERD
Interventions
Cytosponge, Transnasal Endoscopy (TNE), Esophagogastroduodenoscopy
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2023 · Synced Sep 5, 2026, 9:29 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Adults

NCT03142867
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Interventions
non-applicable
Other
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
826 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 5, 2026, 9:29 AM EDT
Completed Phase 1 Interventional Results available

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

NCT03558139
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Magrolimab, Avelumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Chicago, Illinois • Grand Rapids, Michigan • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2024 · Synced Sep 5, 2026, 9:29 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

NCT05835011
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Decitabine/Cedazuridine, Magrolimab
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
New Haven, Connecticut • Plantation, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 5, 2026, 9:29 AM EDT
Terminated Phase 2 Interventional Results available

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

NCT00726232
View directory record Official record
Conditions
Myeloproliferative Neoplasm (MPN)
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 5, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

NCT01327053
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
LDE225
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
22
States / cities
Fayetteville, Arkansas • Los Angeles, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 5, 2026, 9:29 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

NCT01428219
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Cabozantinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 5, 2026, 9:29 AM EDT
Completed Phase 4 Interventional Results available

Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia

NCT01165307
View directory record Official record
Conditions
Menorrhagia
Interventions
Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation
Drug · Device
Lead sponsor
Abimbola Famuyide
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 5, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

NCT04632992
View directory record Official record
Conditions
Advanced Unresectable or Metastatic Solid Malignancy
Interventions
Entrectinib, Inavolisib, Alectinib, Ipatasertib, Atezolizumab, Trastuzumab Emtansine, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Tucatinib, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, Pralsetinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
38
States / cities
Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 5, 2026, 9:29 AM EDT
Recruiting Early Phase 1 Interventional

Regional Monitoring of CF Lung Disease

NCT06339593
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Airway-clearance vest, Hyperpolarized Xe129
Procedure · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 5, 2026, 9:29 AM EDT
Not listed Phase 2 Interventional Results available

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04033432
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Prostate Adenocarcinoma, Progressive Disease, Prostate Carcinoma Metastatic in the Bone, Prostate Carcinoma Metastatic in the Soft Tissue, PSA Progression, Stage IVB Prostate Cancer AJCC v8, Testosterone Less Than 50 ng/dL
Interventions
Recombinant EphB4-HSA Fusion Protein
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 5, 2026, 9:29 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Comparing NicoBloc to Nicotine Lozenges

NCT03720899
View directory record Official record
Conditions
Smoking Cessation, Nicotine Dependence
Interventions
NicoBloc, Nicotine Lozenge
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 5, 2026, 9:29 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects

NCT02391571
View directory record Official record
Conditions
Withdrawal Symptoms
Interventions
Oxycodone/Naltrexone Capsules, Oxycodone, Placebo
Drug
Lead sponsor
Elite Laboratories, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 5, 2026, 9:29 AM EDT
Recruiting Phase 4 Interventional

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

NCT06610305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 5, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens

NCT00218127
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Levoacetyl Methadol
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
25 Years to 55 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 5, 2026, 9:29 AM EDT
Completed Not applicable Interventional

Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy

NCT00038259
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 5, 2026, 9:29 AM EDT